null

null

null

null

null

null

null

null

null

Low leverage; ~$0 long-term debt as of 2023, ~$2B+ cash/investments; 20% rate rise has negligible P&L impact

Minimal debt-service sensitivity; rising rates modestly boost interest income on $2B+ cash portfolio, net positive effect

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) API manufacturing APIs sourced from limited CMOs; 2) Lung xenotransplantation organs depend on proprietary gene-edited pig herds (single-source)

~85% US revenue; EU/Canada/Japan minor contributors; sovereign currency devaluation risk is low given USD-denominated dominance

Predominantly US (~85%+ revenue); limited FX exposure in EU and Canada; Japan minimal; currency devaluation risk is low

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Smiths Medical/specialty CMOs for treprostinil delivery devices represent meaningful single-source risk; device dependency is non-trivial

Specialty biopharmaceutical manufacturer/seller; cloud disruption would affect back-office only; core manufacturing is on-premise/physical

Organ manufacturing/xenotransplantation pipeline; not cloud-dependent; physical biotech infrastructure dominates operational risk

Low API coupling risk; internal IT systems standard; patient-side switching costs high due to clinical inertia and payer formulary lock-in

Not applicable; revenue from FDA-approved drug sales and services; no investment contract or token structure; Howey risk is null

Very High

Moderate HIPAA exposure; limited GDPR risk given small EU commercial footprint; CCPA relevant for US patient data; compliance infrastructure in place

Moderate; Remodulin/Orenitram face scrutiny over drug pricing and orphan drug exclusivity extensions; FTC watch on rare-disease pricing

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~90%+ recurring via long-term specialty pharmacy and hub-service contracts; PAH patients remain on therapy indefinitely; highly recurring

Per-prescription/per-unit drug sales through specialty pharmacy channels; some device/delivery system bundled revenue

Orphan-drug pricing model; Remodulin list price ~$100K–$300K/year per patient; highly inelastic demand; payer negotiation limits downside risk

High; orphan disease designation, limited substitutes, life-sustaining therapy; 9/10 pricing power in rare PAH segment

87.9% Gross Margin (Premium (>60%))

Near-zero free-rider risk; prescription therapy requires physician oversight and specialty pharmacy; no freemium or open-access leakage

Sublinear; manufacturing and R&D scale with capital investment, not proportionally with headcount; commercial team already covers addressable PAH market

Low marginal cost for existing drugs; growth via new indications (xenotransplantation) is capital-intensive R&D, not headcount-linear

Not applicable; not a franchise business model; direct specialty pharma sales and company-owned manufacturing

At 10x scale, CAC economics improve; PAH physician universe is small (~5,000 specialists); patient pool expansion requires new indications

Weak traditional network effects; clinical data/outcomes network effect exists as registry data strengthens label and payer coverage

21.8% Return on Assets (Strong)

Tier 1 recession-resistant; life-sustaining PAH therapies are non-discretionary; payer coverage stable even in downturns

Pulmonary arterial hypertension (PAH) patients (~50,000 in US); highly concentrated rare disease population

Specialty pharmacies and hospital systems acting as distribution intermediaries; top 3 specialty pharmacies handle majority of dispensing volume

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

16.4% CapEx / Revenue (High-CapEx Infrastructure)

0001082554

UTHR